Abstract
1285
Objectives With the development of endocrine therapies and targeted therapie, evaluation for hormone receptor status such as estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) are required before therapy. FDG-PET is clinically used in evaluating breast cancer. However, there were a few studies evaluating the correlation between hormone receptor status and FDG uptake. The purpose of this study was to evaluate the correlation between FDG uptake in breast cancer and ER, PR and HER2 status during breast cancer staging.
Methods We retrospectively reviewed data for patients with newly diagnosed breast cancer who had undergone FDG-PET and ER, PR and HER2 status evaluation before any therapeutic intervention between 2006 and 2008. FDG-PET was performed within 1 week of hormone receptor and HER2 evaluation. Any expression of ER or PR greater than 1% was considered positive. HER2 values of 0 or 1 were considered negative and values of 3 were considered positive. Hormone receptor status was grouped as ER positive and ER negative group, PR positive and negative group, and HER2 positive and negative group. These groups were correlated with FDG uptake.
Results The study involved 119 patients. ER-negative tumors had significant higher FDG uptake than ER-positive tumor (p=0.025). By contrast, there was no significant correlation between FDG uptake and PR status (p=0.151) and HER2 status (p= 0.334). Triple negative breast cancer had significantly higher FDG uptake than ER-positive PR-positive HER2-negative group (p=0.002), ER-negative PR-negative HER2-positive group (p=0.005) and ER-positive PR-positive HER2-positive group (p=0.003).
Conclusions In primary breast cancer, FDG uptake was well correlated with ER status. Triple negative breast cancer which has aggressive biology had significantly higher FDG uptake than other breast cancers
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.